NCT04884906

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

A Single-arm, Single-center, Open, Prospective Phase II Clinical Study of Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer

Detailed description

This study is a single-arm, single-center, open, prospective phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer.

Conditions

• Locally Advanced Cervical Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Camrelizumab	200mg/m2, iv, d1, Q3W, a total of 6 cycles
RADIATION	radiotherapy	1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
DRUG	Albumin Paclitaxel	260mg/m2, iv, d1, Q3W, a total of 6 cycles
DRUG	Cisplatin	80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles

Timeline

• Start date: 2020-11-01
• Primary completion: 2022-11-01
• Completion: 2024-11-01
• First posted: 2021-05-13
• Last updated: 2021-05-13

Locations

1 site across 1 country: China